ESMO 2022 on the Updated OS From the Phase 3 TOPAZ-1 Study: Durvalumab/Placebo + Gemcitabine & Cisplatin in Advanced Biliary Tract Cancer

167 views
September 19, 2022
Comments 0
Login to view comments. Click here to Login